# Bacil Pharma (NSE: BACPHAR) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/BACPHAR · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹58 Cr, it ranks 2985th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 1.6% in FY25. Promoters held 0.00% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹58 Cr |
| ROE | 1.6% (FY25) |
| ROCE | 1.6% (FY25) |
| Debt to equity | 0.01 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹0 Cr | ₹0 Cr |
| FY24 | ₹0 Cr | −₹0 Cr |
| FY23 | ₹0 Cr | −₹0 Cr |
| FY22 | ₹0 Cr | −₹4 Cr |
| FY21 | ₹0 Cr | −₹0 Cr |
| FY20 | ₹0 Cr | −₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 0.00%
- Non-institutions: 100.00%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Samrat Pharma](https://app.pivotnow.in/stock/SAMRATPH) | — | ₹61 Cr | — | — |
| [Royal Sense](https://app.pivotnow.in/stock/ROYAL) | — | ₹59 Cr | — | — |
| [Veerhealth Care](https://app.pivotnow.in/stock/VEERHEALTH) | — | ₹58 Cr | — | — |
| [Constronics Inf](https://app.pivotnow.in/stock/CONSTRONIC) | — | ₹57 Cr | — | — |
| [Kabra Drugs](https://app.pivotnow.in/stock/KABRADG) | — | ₹56 Cr | — | — |
| [Bandaram Pharma](https://app.pivotnow.in/stock/BANDARAM) | — | ₹53 Cr | — | — |

## Questions and answers

### What is the market cap of Bacil Pharma?

Bacil Pharma's market capitalisation is ₹58 Cr (₹58 Cr) at the 22 Oct 2026 close, ranking 2985th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Bacil Pharma?

Return on equity was 1.6% in FY25 and return on capital employed was 1.6% in FY25 (standalone figures).

### Is Bacil Pharma a debt-free company?

Bacil Pharma is close to debt-free: its debt-to-equity ratio was 0.01 in FY25.

### What is the shareholding pattern of Bacil Pharma?

As of 30 Jun 2026: promoters 0.00%, non-institutions 100.00%.

### Who are Bacil Pharma's competitors?

The listed Pharma & Healthcare companies closest to Bacil Pharma by market cap are Samrat Pharma, Royal Sense, Veerhealth Care, Constronics Inf, Kabra Drugs and Bandaram Pharma.

### Is Bacil Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Bacil Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BACPHAR against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.